Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
0.556
+0.046 (9.00%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.

The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.

It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd.
Sol-Gel Technologies logo
Country Israel
Founded 1997
IPO Date Jan 23, 2018
Industry Biotechnology
Sector Healthcare
Employees 36
CEO Alon Seri-Levy

Contact Details

Address:
7 Golda Meir Street, Weizmann Science Park
Ness Ziona, 7403650
Israel
Phone 972 8 931 3433
Website sol-gel.com

Stock Details

Ticker Symbol SLGL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001684693
CUSIP Number M8694L103
ISIN Number IL0011417206
SIC Code 2834

Key Executives

Name Position
Dr. Alon Seri-Levy Co-Founder, Chief Executive Officer and Director
Dr. Itzik Yosef Chief Operating Officer
Gilad Mamlok Advisor
Moshe Arkin Executive Chairman of the Board
Prof. David Avnir Co-Founder
Eyal Ben-Or Chief Financial Officer
Tamar Fishman Jutkowitz Vice President and General Counsel
Dr. Karine Neimann Vice President of Projects and Planning and Chief Chemist

Latest SEC Filings

Date Type Title
Nov 4, 2024 6-K Report of foreign issuer
Sep 25, 2024 6-K Report of foreign issuer
Aug 27, 2024 6-K Report of foreign issuer
Aug 19, 2024 424B3 Prospectus
Aug 19, 2024 6-K/A Filing
Aug 16, 2024 6-K Report of foreign issuer
Jul 25, 2024 6-K Report of foreign issuer
Jul 22, 2024 6-K Report of foreign issuer
Jul 15, 2024 6-K Report of foreign issuer
May 28, 2024 6-K Report of foreign issuer